<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815996</url>
  </required_header>
  <id_info>
    <org_study_id>407-2012</org_study_id>
    <secondary_id>IRB201702171</secondary_id>
    <nct_id>NCT01815996</nct_id>
  </id_info>
  <brief_title>Identify Clinical Conditions That Increase Circulating DNA Levels</brief_title>
  <acronym>BARDA II</acronym>
  <official_title>Identify Clinical Conditions That Increase Circulating DNA Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are developing a test that is expected to measure the amount of radiation a&#xD;
      patient has been exposed to after a nuclear bomb. The investigator will do this by measuring&#xD;
      the DNA in the patients blood from cells killed by the radiation.&#xD;
&#xD;
      Many diseases and medical conditions can put DNA in the blood. The investigator needs to know&#xD;
      how much DNA in order to better interpret our radiation detection test. Therefore, the&#xD;
      investigator is collecting blood from several patients with different diseases or medical&#xD;
      conditions and also healthy volunteers to measure their DNA content.&#xD;
&#xD;
      Patients that will be included in this study are pregnant women, patients who have suffered a&#xD;
      pulmonary embolism within the past 48 hours, patients who have suffered from myocardial&#xD;
      infarction in the past 48 hours, patients with autoimmune diseases and health patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will collect 8 mL (one and one half teaspoons) of blood one time only. The&#xD;
      investigator may also collect the patient's past medical history, test results and disease&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">July 28, 2016</completion_date>
  <primary_completion_date type="Actual">July 28, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Different diseases will be analysed for the levels of DNA circulating in the blood</measure>
    <time_frame>blood will be tested up to 1 year after collection</time_frame>
    <description>To determine what medical conditions and disease states might increase circulating DNA levels at a magnitude similar to whole body irradiation.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Pregnancy</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
    <description>Females between the age of 18-80 who are pregnant&#xD;
One time blood draw to look at patient's DNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Embolism Patients</arm_group_label>
    <description>Male and Female patients that have suffered a pulmonary embolism within the past 48 hours&#xD;
One time blood draw to look at patient's DNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myocardial Patients</arm_group_label>
    <description>Male and Female patients who have myocardial infarction in the past 48 hours.&#xD;
One time blood draw to look at patient's DNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune Patients</arm_group_label>
    <description>Male and Female patients that have been diagnosed with an Autoimmune disease&#xD;
One time blood draw to look at patient's DNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Self-declared healthy adults (men and women).&#xD;
One time blood draw to look at patient's DNA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>One time blood draw to look at patient's DNA</intervention_name>
    <description>One time blood draw to look at patient's DNA</description>
    <arm_group_label>Autoimmune Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Myocardial Patients</arm_group_label>
    <arm_group_label>Pregnant Women</arm_group_label>
    <arm_group_label>Pulmonary Embolism Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4-5 ml of blood will be processed and the plasma will be divided into 150 Î¼l aliquots&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Seeking healthy volunteers, pregnant women, patients who recently suffered a heart attach&#xD;
        or pulmonary embolism, and patiebts with autoimmune disease. Patients who are health&#xD;
        individuals will also be asked to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be adults in one of the following categories:&#xD;
&#xD;
               -  Pregnant&#xD;
&#xD;
               -  Suffered a pulmonary embolism within the past 48 hours&#xD;
&#xD;
               -  Myocardial infarction in the past 48 hours&#xD;
&#xD;
               -  Diagnosed with an autoimmune disease&#xD;
&#xD;
               -  Adults age 18-80&#xD;
&#xD;
               -  Self-declared healthy adults&#xD;
&#xD;
          2. Patients must be willing to undergo a blood draw&#xD;
&#xD;
          3. Patients must provide study-specific informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients not meeting the above inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Okunieff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shands Davis Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>autoimmune disease</keyword>
  <keyword>healthy controls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

